Upcoming events – Anaptysbio and Retrophin await big readouts
Anaptysbio’s etokimab needs to beat Dupixent, while Retrophin takes aims at an underserved rare disease.
Go or no go? Merck, Regeneron and Alexion await US expansion
Approvals for new uses of old drugs should far outweigh nods for novel projects in June.
